{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T06:17:30Z","timestamp":1774851450733,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s10549-026-07945-1","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T01:14:11Z","timestamp":1774314851000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rb expression in metastatic ER-positive breast cancer: implications for precision oncology"],"prefix":"10.1007","volume":"216","author":[{"given":"Doaa","family":"Morrar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dara","family":"Ross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedram","family":"Razavi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edi","family":"Brogi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fresia","family":"Pareja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah Y.","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher J.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"issue":"5","key":"7945_CR1","doi-asserted-by":"publisher","first-page":"R75","DOI":"10.1186\/bcr2142","volume":"10","author":"JI Herschkowitz","year":"2008","unstructured":"Herschkowitz JI, He X, Fan C, Perou CM (2008) The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas. Breast Cancer Res 10(5):R75. https:\/\/doi.org\/10.1186\/bcr2142","journal-title":"Breast Cancer Res"},{"issue":"7155","key":"7945_CR2","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1038\/nature06046","volume":"448","author":"D Santamar\u00eda","year":"2007","unstructured":"Santamar\u00eda D, Barri\u00e8re C, Cerqueira A et al (2007) Cdk1 is sufficient to drive the mammalian cell cycle. Nature 448(7155):811\u2013815. https:\/\/doi.org\/10.1038\/nature06046","journal-title":"Nature"},{"issue":"5293","key":"7945_CR3","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1126\/science.274.5293.1672","volume":"274","author":"CJ Sherr","year":"1996","unstructured":"Sherr CJ (1996) Cancer cell cycles. Science 274(5293):1672\u20131677. https:\/\/doi.org\/10.1126\/science.274.5293.1672","journal-title":"Science"},{"issue":"8","key":"7945_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2024.100541","volume":"37","author":"CJ Schwartz","year":"2024","unstructured":"Schwartz CJ, Marra A, Selenica P et al (2024) RB1 genetic alterations in estrogen receptor-positive breast carcinomas: correlation with neuroendocrine differentiation. Mod Pathol 37(8):100541. https:\/\/doi.org\/10.1016\/j.modpat.2024.100541","journal-title":"Mod Pathol"},{"key":"7945_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-020-0160-4","volume":"6","author":"JM Patel","year":"2020","unstructured":"Patel JM, Goss A, Garber JE et al (2020) Retinoblastoma protein expression and its predictors in triple-negative breast cancer. NPJ Breast Cancer 6:19. https:\/\/doi.org\/10.1038\/s41523-020-0160-4","journal-title":"NPJ Breast Cancer"},{"issue":"2","key":"7945_CR6","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1158\/1078-0432.CCR-21-1565","volume":"28","author":"AC Mandigo","year":"2022","unstructured":"Mandigo AC, Tomlins SA, Kelly WK, Knudsen KE (2022) Relevance of pRB loss in human malignancies. Clin Cancer Res 28(2):255\u2013264. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-1565","journal-title":"Clin Cancer Res"},{"issue":"6","key":"7945_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-019-0651-4","volume":"20","author":"CG Murphy","year":"2019","unstructured":"Murphy CG (2019) The role of CDK4\/6 inhibitors in breast cancer. Curr Treat Options Oncol 20(6):52. https:\/\/doi.org\/10.1007\/s11864-019-0651-4","journal-title":"Curr Treat Options Oncol"},{"issue":"12","key":"7945_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002201","volume":"13","author":"C Lefebvre","year":"2016","unstructured":"Lefebvre C, Bachelot T, Filleron T et al (2016) Mutational profile of metastatic breast cancers: a retrospective analysis. PLoS Med 13(12):e1002201. https:\/\/doi.org\/10.1371\/journal.pmed.1002201","journal-title":"PLoS Med"},{"issue":"11","key":"7945_CR9","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1158\/2159-8290.CD-20-1647","volume":"11","author":"P Aftimos","year":"2021","unstructured":"Aftimos P, Oliveira M, Irrthum A et al (2021) Genomic and transcriptomic analyses of breast cancer primaries and matched metastases in AURORA, the Breast International Group (BIG) molecular screening initiative. Cancer Discov 11(11):2796\u20132811. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-1647","journal-title":"Cancer Discov"},{"issue":"8","key":"7945_CR10","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1158\/0008-5472.CAN-15-0728","volume":"76","author":"MT Herrera-Abreu","year":"2016","unstructured":"Herrera-Abreu MT, Palafox M, Asghar U et al (2016) Early adaptation and acquired resistance to CDK4\/6 inhibition in estrogen receptor-positive breast cancer. Cancer Res 76(8):2301\u20132313. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-0728","journal-title":"Cancer Res"},{"issue":"21","key":"7945_CR11","doi-asserted-by":"publisher","first-page":"4702","DOI":"10.1158\/1078-0432.CCR-22-1115","volume":"28","author":"CA Febres-Aldana","year":"2022","unstructured":"Febres-Aldana CA, Chang JC, Ptashkin R et al (2022) Rb tumor suppressor in small cell lung cancer: combined genomic and IHC analysis with a description of a distinct Rb-proficient subset. Clin Cancer Res 28(21):4702\u20134713. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-1115","journal-title":"Clin Cancer Res"},{"issue":"42","key":"7945_CR12","doi-asserted-by":"publisher","first-page":"68012","DOI":"10.18632\/oncotarget.12010","volume":"7","author":"L Malorni","year":"2016","unstructured":"Malorni L, Piazza S, Ciani Y et al (2016) A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer. Oncotarget 7(42):68012\u201368022. https:\/\/doi.org\/10.18632\/oncotarget.12010","journal-title":"Oncotarget"},{"issue":"2","key":"7945_CR13","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s10549-018-4766-2","volume":"170","author":"E Risi","year":"2018","unstructured":"Risi E, Grilli A, Migliaccio I et al (2018) A gene expression signature of Retinoblastoma loss-of-function predicts resistance to neoadjuvant chemotherapy in ER-positive\/HER2-positive breast cancer patients. Breast Cancer Res Treat 170(2):329\u2013341. https:\/\/doi.org\/10.1007\/s10549-018-4766-2","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"7945_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32828-6","volume":"13","author":"M Palafox","year":"2022","unstructured":"Palafox M, Monserrat L, Bellet M et al (2022) High p16 expression and heterozygous RB1 loss are biomarkers for CDK4\/6 inhibitor resistance in ER+ breast cancer. Nat Commun 13(1):5258. https:\/\/doi.org\/10.1038\/s41467-022-32828-6","journal-title":"Nat Commun"},{"issue":"1","key":"7945_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-024-00699-3","volume":"10","author":"N Mai","year":"2024","unstructured":"Mai N, Dos Anjos CH, Razavi P et al (2024) Predictors of response to CDK4\/6i retrial after prior CDK4\/6i failure in ER+ metastatic breast cancer. NPJ Breast Cancer 10(1):92. https:\/\/doi.org\/10.1038\/s41523-024-00699-3","journal-title":"NPJ Breast Cancer"},{"issue":"1","key":"7945_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/srep42056","volume":"7","author":"I Gonzalez-Vasconcellos","year":"2017","unstructured":"Gonzalez-Vasconcellos I, Schneider R, Anastasov N et al (2017) The Rb1 tumour suppressor gene modifies telomeric chromatin architecture by regulating TERRA expression. Sci Rep 7(1):42056. https:\/\/doi.org\/10.1038\/srep42056","journal-title":"Sci Rep"},{"issue":"4","key":"7945_CR17","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/j.1365-2559.2006.02513.x","volume":"49","author":"CR Taylor","year":"2006","unstructured":"Taylor CR, Levenson RM (2006) Quantification of immunohistochemistry--issues concerning methods, utility and semiquantitative assessment II. Histopathology 49(4):411\u2013424. https:\/\/doi.org\/10.1111\/j.1365-2559.2006.02513.x","journal-title":"Histopathology"},{"issue":"7","key":"7945_CR18","doi-asserted-by":"publisher","first-page":"189","DOI":"10.62347\/HGNI4903","volume":"17","author":"Y Xue","year":"2024","unstructured":"Xue Y, Zhai J (2024) Strategy of combining CDK4\/6 inhibitors with other therapies and mechanisms of resistance. Int J Clin Exp Pathol 17(7):189\u2013207. https:\/\/doi.org\/10.62347\/HGNI4903","journal-title":"Int J Clin Exp Pathol"},{"issue":"2","key":"7945_CR19","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/his.14091","volume":"77","author":"PH Tan","year":"2020","unstructured":"Tan PH, Ellis I, Allison K et al (2020) The 2019 World Health Organization classification of tumours of the breast. Histopathology 77(2):181\u2013185. https:\/\/doi.org\/10.1111\/his.14091","journal-title":"Histopathology"},{"issue":"9","key":"7945_CR20","doi-asserted-by":"publisher","first-page":"991","DOI":"10.5858\/arpa.2023-0187-ED","volume":"147","author":"SJ Schnitt","year":"2023","unstructured":"Schnitt SJ, Tarantino P, Collins LC (2023) The American Society of Clinical Oncology-College of American Pathologists guideline update for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 147(9):991\u2013992. https:\/\/doi.org\/10.5858\/arpa.2023-0187-ED","journal-title":"Arch Pathol Lab Med"},{"issue":"5","key":"7945_CR21","doi-asserted-by":"publisher","first-page":"545","DOI":"10.5858\/arpa.2019-0904-SA","volume":"144","author":"KH Allison","year":"2020","unstructured":"Allison KH, Hammond MEH, Dowsett M et al (2020) Estrogen and progesterone receptor testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists guideline update. Arch Pathol Lab Med 144(5):545\u2013563. https:\/\/doi.org\/10.5858\/arpa.2019-0904-SA","journal-title":"Arch Pathol Lab Med"},{"issue":"3","key":"7945_CR22","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jmoldx.2014.12.006","volume":"17","author":"DT Cheng","year":"2015","unstructured":"Cheng DT, Mitchell TN, Zehir A et al (2015) Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. J Mol Diagn 17(3):251\u2013264. https:\/\/doi.org\/10.1016\/j.jmoldx.2014.12.006","journal-title":"J Mol Diagn"},{"issue":"22","key":"7945_CR23","doi-asserted-by":"publisher","first-page":"15818","DOI":"10.18632\/oncotarget.24530","volume":"9","author":"LF Sallum","year":"2018","unstructured":"Sallum LF, Andrade L, Ramalho S et al (2018) WT1, p53 and p16 expression in the diagnosis of low- and high-grade serous ovarian carcinomas and their relation to prognosis. Oncotarget 9(22):15818\u201315827. https:\/\/doi.org\/10.18632\/oncotarget.24530","journal-title":"Oncotarget"},{"issue":"18","key":"7945_CR24","doi-asserted-by":"publisher","first-page":"5110","DOI":"10.1158\/1078-0432.CCR-12-0903","volume":"18","author":"AK Witkiewicz","year":"2012","unstructured":"Witkiewicz AK, Ertel A, McFalls J, Valsecchi ME, Schwartz G, Knudsen ES (2012) RB-pathway disruption is associated with improved response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res 18(18):5110\u20135122. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-0903","journal-title":"Clin Cancer Res"},{"issue":"22","key":"7945_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222212292","volume":"22","author":"ER Scheidemann","year":"2021","unstructured":"Scheidemann ER, Shajahan-Haq AN (2021) Resistance to CDK4\/6 inhibitors in estrogen receptor-positive breast cancer. Int J Mol Sci 22(22):12292. https:\/\/doi.org\/10.3390\/ijms222212292","journal-title":"Int J Mol Sci"},{"issue":"5","key":"7945_CR26","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1111\/his.12306","volume":"64","author":"SY Kwon","year":"2014","unstructured":"Kwon SY, Bae YK, Gu MJ et al (2014) Neuroendocrine differentiation correlates with hormone receptor expression and decreased survival in patients with invasive breast carcinoma. Histopathology 64(5):647\u2013659. https:\/\/doi.org\/10.1111\/his.12306","journal-title":"Histopathology"},{"issue":"8","key":"7945_CR27","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1158\/1078-0432.CCR-24-2647","volume":"31","author":"S Goel","year":"2025","unstructured":"Goel S, Jovanovi\u0107 B, Chu X et al (2025) A phase II study of Abemaciclib for patients with Retinoblastoma-Positive, metastatic Triple-Negative Breast Cancer. Clin Cancer Res 31(8):1427\u20131436. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-2647","journal-title":"Clin Cancer Res"},{"issue":"7","key":"7945_CR28","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1111\/his.15169","volume":"84","author":"N Yasutake","year":"2024","unstructured":"Yasutake N, Yamamoto H, Kuga R et al (2024) Immunohistochemical p16 overexpression and Rb loss correlate with high-risk Human Papillomavirus infection in endocervical adenocarcinomas. Histopathology 84(7):1178\u20131191. https:\/\/doi.org\/10.1111\/his.15169","journal-title":"Histopathology"},{"issue":"9","key":"7945_CR29","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1080\/15592294.2020.1834911","volume":"16","author":"AM Raizis","year":"2021","unstructured":"Raizis AM, Racher HM, Foucal A, Dimaras H, Gallie BL, George PM (2021) DNA hypermethylation\/boundary control loss identified in retinoblastomas associated with genetic and epigenetic inactivation of the RB1 gene promoter. Epigenetics 16(9):940\u2013954. https:\/\/doi.org\/10.1080\/15592294.2020.1834911","journal-title":"Epigenetics"},{"issue":"1","key":"7945_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-22312-x","volume":"8","author":"L Lupini","year":"2018","unstructured":"Lupini L, Moretti A, Bassi C et al (2018) High-sensitivity assay for monitoring ESR1 mutations in circulating cell-free DNA of breast cancer patients receiving endocrine therapy. Sci Rep 8(1):4371. https:\/\/doi.org\/10.1038\/s41598-018-22312-x. (Published 2018 Mar 12)","journal-title":"Sci Rep"},{"issue":"16","key":"7945_CR31","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1158\/1078-0432.CCR-21-3189","volume":"28","author":"Y Xia","year":"2022","unstructured":"Xia Y, He X, Renshaw L et al (2022) Integrated DNA and RNA sequencing reveals drivers of endocrine resistance in Estrogen Receptor-Positive Breast Cancer. Clin Cancer Res 28(16):3618\u20133629. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-3189","journal-title":"Clin Cancer Res"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-07945-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-026-07945-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-07945-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T04:55:29Z","timestamp":1774846529000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-026-07945-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["7945"],"URL":"https:\/\/doi.org\/10.1007\/s10549-026-07945-1","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]},"assertion":[{"value":"24 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"FP reports consulting fees from AstraZeneca and Multiplex DX outside the submitted work. All other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"36"}}